Impedance-based cellular assay technologies: recent advances, future promise.
Cell-based assays are continuing to grow in importance in the drug discovery workflow. Their early introduction holds the promise of limiting attrition in the later, more costly phases of the process. This article reviews recent advances in the development of impedance technologies for label-free cell-based assays. These systems are capable of monitoring endogenous receptor activation, and thus generate more physiologically relevant measures of pharmacological endpoints. Primary cells can be investigated as well, thus producing disease relevant information. Label-free assays significantly decrease assay development efforts and avoid many complications inherent in recombinant readout systems. Impedance-based systems have great potential to advance the utility of cell-based assays as they are applied to drug discovery and pharmacology.
McGuinness
Ryan
R
MDS Analytical Technologies, Drug Discovery, 1311 Orleans Drive, Sunnyvale, CA 94089, United States. ryan.mcguinness@moldev.com
D001681:Biological Assay; D017097:Electric Impedance; D006801:Humans; D020794:Receptor Protein-Tyrosine Kinases / Q000378:metabolism; D043562:Receptors, G-Protein-Coupled / Q000378:metabolism
D043562:Receptors, G-Protein-Coupled; D020794:Receptor Protein-Tyrosine Kinases